AU2001234730A1 - Method for inhibiting complement activation - Google Patents
Method for inhibiting complement activationInfo
- Publication number
- AU2001234730A1 AU2001234730A1 AU2001234730A AU3473001A AU2001234730A1 AU 2001234730 A1 AU2001234730 A1 AU 2001234730A1 AU 2001234730 A AU2001234730 A AU 2001234730A AU 3473001 A AU3473001 A AU 3473001A AU 2001234730 A1 AU2001234730 A1 AU 2001234730A1
- Authority
- AU
- Australia
- Prior art keywords
- complement activation
- inhibiting complement
- inhibiting
- activation
- complement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000024203 complement activation Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17954300P | 2000-02-01 | 2000-02-01 | |
US60179543 | 2000-02-01 | ||
PCT/US2001/003296 WO2001057184A2 (en) | 2000-02-01 | 2001-02-01 | Use of platelet activity modulators for inhibiting complement activation |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001234730A1 true AU2001234730A1 (en) | 2001-08-14 |
Family
ID=22657027
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001234730A Abandoned AU2001234730A1 (en) | 2000-02-01 | 2001-02-01 | Method for inhibiting complement activation |
Country Status (3)
Country | Link |
---|---|
US (2) | US6538028B1 (en) |
AU (1) | AU2001234730A1 (en) |
WO (1) | WO2001057184A2 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6538028B1 (en) * | 2000-02-01 | 2003-03-25 | Vanderbilt University | Method for inhibiting complement activation |
US6716962B2 (en) * | 2000-07-17 | 2004-04-06 | Micrologix Biotech Inc. | Extractive purification of lipopeptide antibiotics |
US20040244062A1 (en) * | 2003-06-02 | 2004-12-02 | Crittenden Jill R. | Use of protein inhibitors as antithrombotic agents |
US7141544B2 (en) * | 2003-10-10 | 2006-11-28 | Baxter International, Inc. | Stabilization of pharmaceutical protein formulations with small peptides |
PL1755674T3 (en) * | 2004-05-14 | 2015-05-29 | Alexion Pharma Inc | Prolongation of survival of an allograft by inhibiting complement activity |
US20070196367A1 (en) * | 2006-02-22 | 2007-08-23 | Valentin Dinu | Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system |
CN101437501B (en) * | 2006-03-02 | 2012-09-05 | 阿莱克申药物公司 | Prolongation of survival of an allograft by inhibiting complement activity |
ES2475199T3 (en) | 2008-09-16 | 2014-07-10 | Imuneks Farma Ila� Sanayi Ve Ticaret A.S. | Use of opioid antagonists for the preparation of a medicine in the treatment of degenerative diseases of the retina |
WO2011040894A1 (en) * | 2009-10-01 | 2011-04-07 | Mustafa Nevzat Ilaç Sanayii A.Ş. | Topical compositions of opioid antagonists and methods for treating skin conditions therewith |
TR201002473A2 (en) | 2010-03-31 | 2011-09-21 | Mustafa Nevzat �La� Sanay�� A.�. | A method of treating herpes zoster disease using an opiate receptor antagonist. |
US10588879B2 (en) | 2011-08-01 | 2020-03-17 | Aurin Biotech Inc. | Treatment of age-related macular degeneration |
US10966945B2 (en) | 2011-08-01 | 2021-04-06 | Aurin Biotech Inc. | Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic synthetic complex |
CN104661660A (en) * | 2012-07-13 | 2015-05-27 | 奥林生物技术股份有限公司 | Selective inhibition of the membrane attack complex of complement and C3 convertase by low molecular weight components of the aurin tricarboxylic acid synthetic complex |
US8877808B2 (en) * | 2012-12-06 | 2014-11-04 | Aurin Biotech Inc. | Protection against skin diseases by aurin tricarboxylic acid and its derivatives |
US10004707B2 (en) | 2014-04-15 | 2018-06-26 | Aurin Biotech Inc. | Method for treating cancer with low molecular weight components of aurin tricarboxylic acid complex |
US11013750B2 (en) | 2017-01-20 | 2021-05-25 | Aurin Biotech Inc. | Methods for treating and preventing nociceptive pain |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4007270A (en) | 1975-11-18 | 1977-02-08 | American Cyanamid Company | Complement inhibitors |
IL79254A0 (en) | 1986-06-26 | 1986-09-30 | Hadassah Med Org | Compositions for preventing graft rejection |
US4880788A (en) | 1987-10-30 | 1989-11-14 | Baylor College Of Medicine | Method for preventing and treating thrombosis |
US5573940A (en) | 1989-06-12 | 1996-11-12 | Oklahoma Medical Research Foundation | Cells expressing high levels of CD59 |
US5135916A (en) | 1989-06-12 | 1992-08-04 | Oklahoma Medical Research Foundation | Inhibition of complement mediated inflammatory response |
US5589582A (en) | 1992-10-27 | 1996-12-31 | Biotransplant, Inc. | Polynucleotides en coding porcine cytokines |
US5434185A (en) | 1993-05-17 | 1995-07-18 | The University Of Kentucky Research Foundation | Method for inhibiting angiogenesis with aurintricarboxylic acid, its analogues or salts |
DE4338793A1 (en) | 1993-11-12 | 1995-05-18 | Froelich Juergen C | L-arginine and analogues as platelet aggregation inhibitors |
JP3110931B2 (en) | 1993-12-28 | 2000-11-20 | 第一製薬株式会社 | Argatroban preparation with smooth muscle cell growth inhibitory action |
US5891645A (en) | 1994-06-01 | 1999-04-06 | Alexion Pharmaceuticals, Inc. | Porcine E-selectin |
US5679345A (en) * | 1994-06-02 | 1997-10-21 | The Johns Hopkins University | Method for preventing complement-dependent rejection of organ or tissue transplants |
US6538028B1 (en) * | 2000-02-01 | 2003-03-25 | Vanderbilt University | Method for inhibiting complement activation |
-
2001
- 2001-02-01 US US09/775,094 patent/US6538028B1/en not_active Expired - Fee Related
- 2001-02-01 WO PCT/US2001/003296 patent/WO2001057184A2/en active Application Filing
- 2001-02-01 AU AU2001234730A patent/AU2001234730A1/en not_active Abandoned
-
2002
- 2002-12-02 US US10/307,813 patent/US20030144358A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US6538028B1 (en) | 2003-03-25 |
US20030144358A1 (en) | 2003-07-31 |
WO2001057184A3 (en) | 2002-04-25 |
WO2001057184A2 (en) | 2001-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001259056A1 (en) | Method for selectively inhibiting ghrelin action | |
AU2001245283A1 (en) | Methods for treating aneurysms | |
AU2001258771A1 (en) | -secretase inhibitors | |
AU2001295030A1 (en) | Adaptive method for polling | |
AU2002239660A1 (en) | Watermaking holograms | |
AU2001231104A1 (en) | Methods for treating diabetes | |
AU2002210881A1 (en) | Transdermal method | |
AU2001234730A1 (en) | Method for inhibiting complement activation | |
AU2002216966A1 (en) | Sludge inerting method | |
AU2001227140A1 (en) | Method for inhibiting apoptosis under ischemic condition | |
AUPR152100A0 (en) | Method for treating coral | |
AU2001233699A1 (en) | Method for selecting products | |
AU2608301A (en) | Methods for inhibiting mastocytosis | |
AU2001229461A1 (en) | Method for inhibiting a tumor | |
AU2001291313A1 (en) | Process for making 3-amino-2-chloro-4-methylpyridine | |
AU2002214487A1 (en) | Method for inducing apoptiosis | |
AU2001220281A1 (en) | Rollerboard for road-skiing | |
AU2001237530A1 (en) | Method | |
AU2224001A (en) | Hologram forming method | |
AU2001241636A1 (en) | Halotherapy method | |
AU2001243297A1 (en) | Method for treating or preventing depression | |
AU2002220757A1 (en) | Method for obtaining azaerythromycin | |
AU2001267769A1 (en) | Process | |
AU2002228911A1 (en) | Methods for inhibiting pain | |
AU5552200A (en) | Method |